Earnings Releases·Nov 10, 2026, 4:18 PM ET

BridgeBio Oncology Therapeutics, Inc. — Third Quarter 2026 Earnings Summary

Reported net loss of $34.2 million ($0.43 per share) for Q3 2026, a significant improvement from $44.8 million ($1.03 per share) in the prior year period, driven by a 24% reduction in total operating expenses to $37.5 million.
Cash and marketable securities decreased to $315.3 million as of September 30, 2026, from $425.5 million at year-end 2025, though management confirms a cash runway extending into 2029.
Clinical progress includes a 75% objective response rate for BBO-8520 in KRASG12C inhibitor-experienced NSCLC patients and the initiation of dosing for BBO-11818 and BBO-10203 combination cohorts in colorectal and pancreatic cancers.
Upcoming data catalysts include monotherapy updates for BBO-11818 and BBO-10203 scheduled for Q4 2026, with multiple additional catalysts expected through mid-2027.
No major strategic M&A or capital-return announcements were disclosed; the company continues to prioritize internal combination strategies targeting RAS-pathway malignancies.